Extended mirikizumab dose produces UC response in initial nonresponders

Additional, extended treatment with mirikizumab helped produce a clinical response in patients with ulcerative colitis who initially did not respond to treatment, according to study results.
William J. Sandborn, MD, of the University of California, San Diego, and colleagues wrote that the drug (Lilly) has previously shown clinical efficacy in phase 2 studies of psoriasis and Crohn’s disease.
“Induction regimens evaluated in most clinical trials are no more than 12 weeks, and some patients, especially those less responsive to initial induction treatment, could potentially improve

Source link

Related posts

Building community in the gut: a role for mucosal serotonin


CKD following acute kidney injury impairs cirrhosis clinical outcomes


AI bests non-expert endoscopists in Barrett’s neoplasia detection


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World